CSNK2B, which encodes the beta subunit of casein kinase II (CK2), plays an important role in neuron morphology and synaptic transmission. Variants in CSNK2B associated with epilepsy and/or intellectual disability (ID)/developmental delay (DD) have been reported in five cases only. Among the 816 probands suspected hereditary epilepsy whose initial report of trio-based whole exome sequencing (WES) were negative, 10 de novo pathogenic or likely pathogenic variants of CSNK2B in nine probands were identified after reanalysis of their raw Trio-WES data. Six of the nine epileptic patients had ID/ DD. the age of seizure onset of these nine patients with CSNK2B variants ranged from 2-12 months. Eight patients had age of seizure onset of less than 6 months. The epilepsy of most probands (8/9) was generalized tonic-clonic seizure and clustered (6/9). Most patients had normal electroencephalogram (5/9) and brain magnetic resonance image (7/9) results. Most patients (7/9) had easy-to-control seizures. Levetiracetam was the most commonly used drug in seizure-free patients (5/7). The variants detected in five patients (5/9, 55.6%) were located in the zinc-binding domain. In summary, our research provided evidence that variants in CSNK2B are associated with epilepsy with or without iD/DD. CSNK2B-related epilepsy is relatively easy to be controlled. the zinc-binding domain appears to be the hotspot region for mutation.
Variant re-analysis. We re-analysis all these trio-WES data. For each sample, exome capture was performed using xGen Exome Research Panel v1.0, which consists of 429,826 individually synthesised, and quality-controlled xGen Lockdown Probes. The captured libraries were sequenced using Illumina Novaseq. 6000 sequencer at 100× coverage. The reads were mapped to the Ensemble GRCh37/hg19 by using Burrows-Wheeler Aligner (BWA 0.7.11) with default parameters. Duplicate reads were marked with Picard Tools, version 2.9.0. Genome Analysis Tool Kit (GATK 3.5) was used for local realignment and base quality score recalibration. Variants were called jointly in all samples by using the GATK's HaplotypeCaller. Variant Effect Predictor (VEP 93) was used to annotate variants with a predicted effect on protein-coding genes.
Variants with a sequencing depth of less than 6× and a variation frequency of less than 10% were filtered. In addition, variants were retained upon satisfying that minimum allele frequency <1% or in their absence in the 1000 Genomes Project, Exome Variant Server, or gnomAD database. Variants that were predicted to be missense, truncating, frameshift, in-frame insertion or deletion, stop codon loss, or splice site disrupting were retained. The ACMG guidelines on variant interpretation and classification were used to determine the variant's pathogenicity 25 .
Results
Identification of de novo CSNK2B variants. Ten de novo CSNK2B variants were found in nine probands and confirmed by Sanger sequencing ( Supplementary Fig. S1 ). All the nine probands suffered from epilepsy with or without ID/DD and had no pathogenic variation found in other epilepsy candidate genes after trio-WES reanalysis, especially SCN1A or PCDH19. The variants found in this study included c.560 T > G (p.L187R), c.620_621insC (p.F207Ffs*39), c.13 G > T (p.E5X, 211), c.256 C > T (p.R86C), c.409 T > G (p.C137G), c.264delC (p.I88Ifs*46), c.410 G > T (p.C137F), c.332 G > C (p.R111P) and c.368-2 A > G in CSNK2B (NM_001320) ( Table 1 ). The variant of c.332 G > C (p.R111P) was identified in two different patients. The variants of c.13 G > T (p.E5X, 211) and c.256 C > T (p.R86C) were identified in patient 3 and were confirmed in the same allele ( Supplementary Fig. S2 ). The variant of c.13 G > T (p.E5X, 211) resulted in a truncation after the first five amino acids. Hence, the pathogenicity of the downstream c.256 C > T (p.R86C) was negligible. The nine novel de novo variants found in this study and the five reported de novo variants are summarised in Fig. 1 . The variants of the six cases occurred in the zinc-binding domain in which two were splicing variants.
Predicted deleterious effect of CSNK2B de novo variants. CSNK2B is highly intolerant to variation.
It has a high probability of LoF intolerance (pLI) score of 0.98 (gnomAD v2.1) and a haploinsufficiency score (%HI) of 5.78 (DECIPHER), indicating that it is extremely LoF intolerant and likely to exhibit haploinsufficiency. CSNK2B is constrained to mis-sense variants (z = 3.09; gnomAD v2.1). We used the DOMINO tool to assess the likelihood of monoallelic variants in CSNK2B to cause a Mendelian disease. CSNK2B had a DOMINO score of 0.835 out of 1, and thus monoallelic mutations likely caused the disease 26 . All these de novo variants have not been found in the gnomAD and 1000 Genomes databases yet. The combined annotation-dependent depletion (CADD) scores were all very high (a score of ≥20 indicates a position within the top 1% most deleterious mutations, and a score of ≥30 indicates a position within the top 0.1% most deleterious mutations) for the variants with CADD scores 27 , indicating that these variants were deleterious. The genomic evolutionary-rate profiling (GERP) 28 scores available for the variant site were all very high (>2 were considered constrained 29 ), indicating that the nucleotide is very conservative. The amino acid residues for the variant site of patients 1, 4, 6, 7 and 8 were highly conserved across species through the sequence alignment downloaded from UniProt (Fig. 2) . The pathogenicity of the identified variants was further predicted through multiple predication tools including PolyPhen2, SIFT, PROVEAN, M-CAP and MutationAssessor (Table 1) . A decrease in MaxEntScan_alt score ≥ 15% compared to the MaxEntScan_ref score is considered to affect splicing 30 . The variant c.368-2 A > G in the 5th intron in the CSNK2B of patient 9 was a canonical splice site variation. The scores for MaxEntScan_alt (MaxEntScan alternate sequence score), MaxEntScan_ref (MaxEntScan reference sequence score) and MaxEntScan_diff (MaxEntScan score difference) were −0.946, 7.009 and 7.955, respectively, indicating that the variation was deleterious. All variants were classified as pathogenic/likely pathogenic on the basis of the guideline proposed by ACMG, which refers to the interpretations from the wInterVar web server ( Table 2) clinical features. Six girls and three boys were included in this study. The seizure onset of these nine patients ranged from 2 months to 12 months. The seizure onset of eight out of nine patients was less than 6 months, indicating an early-onset epilepsy. All nine patients had epilepsy, and six of them had ID/DD. Eight of the nine patients had only one type of seizure, namely, generalised tonic-clonic seizure (GTCS). Seizures were clustered in 66.7% (6/9) patients (patients 2, 3, 4, 5, 6, and 9). We did not find any dysmorphic features in our patients, which was previously reported in two patients 21 . The brain MRIs of patients 1, 4, 5, 6, 7, 8 and 9 were normal. The EEGs of patients 3, 5, 7, 8 and 9 were normal. The EEGs of patients 1, 2 and 6 were abnormal as shown in Fig. 3 . The seizures of most patients were easily controlled, and patients 3, 4, 5, 6, 7, 8 and 9 became seizure free. Levetiracetam Figure 1 . The Variants in CSNK2B DNA Sequence. CSNK2B has 648 nucleotides of coding sequence and contains seven exons. Square endings indicate that exons start or end after a complete codon, arrows to the right indicate that the last base of the last codon is located in the next exon, arrows to the left indicate that the last two bases are located in the exon. The variants in black fonts are from this study and the symbol * indicates that there are two cases with the variant. The variants highlighted in red are from recently reported patients with ID/ DD and epilepsy 20, 21 , the variant highlighted in gold is from recently reported patient with ID 20 , and the variants highlighted in green are from recently reported patient with profound ID and refractory epilepsy 22 . www.nature.com/scientificreports www.nature.com/scientificreports/ (LEV) was the most commonly used drug among seizure-free patients (patients 3, 4, 5, 7 and 8). Four patients became seizure free after monotherapy (patient 5 and 8 with LEV, patient 6 with Valproate [VPA] and patient 9 with topiramate [TPM]). Three patients became seizure free after polytherapy. Patients 3 and 4 became seizure free with LEV and oxcarbazepine (OXC). Patient 7 became seizure free by using TPM, OXC and LEV. Three of the seven seizure-free patients had normal intelligence or developmental milestone, but the other four patients had comorbid ID/DD. Their ID/DD did not improve even after an average of nine seizure-free months (2-15 months). One of the nine patients in this study and two patients reported in a previous study showed myoclonic epilepsy; two of these patients had refractory epilepsy, and another one had epilepsy controlled upon VPA and LEV treatment. The clinical features, electroencephalogram (EEG) and brain magnetic resonance (MRI) of patients with CSNK2B variants are summarised in Table 3 .
Patient 1 had refractory epilepsy and profound ID with an age of seizure onset of 1 year. He is now 6 years and 2 months old, but he cannot utter the word 'Mom' or 'Dad' , and he cannot sit properly. He suffered from severe myoclonic epilepsy, which occurs from dozens to 100 times a day. Only two events of GTCS were observed. The frequency of seizure increased with fever. The EEGs were abnormal at 3 years and 6 months of age with a diffuse slow spike, multiple spike-slow and slow wave discharge. Brain MRI, metabolic assays, array-based Comparative Genomic Hybridization (aCGH), chromosomal karyotype analysis, and mitochondrial DNA analysis were all negative. Multiplex ligation-dependent probe amplification (MLPA) was applied to detect copy number variation (CNV) in SCN1A and the result was negative ( Supplementary Fig. S3A ). We carefully analysed myoclonic epilepsy-related genes by using trio-based WES data, and no pathogenic variation was found ( Supplementary  Table S1 ). VPA and clonazepam were initially used for antiepileptic therapy. The antiepileptic drugs (AEDs) currently used are LEV and TPM. However, epilepsy and ID are not alleviated.
Patient 2 had epilepsy and mild DD. Her Gesell developmental quotient scores were 75 and 70 at 2 years and 2 months and at 3 years and 1 month of age. The type of seizure was GTCS. Seizures occurred four to six times daily for the first three days at the time of epilepsy onset (4 months of age). Each seizure lasted for approximately 30 s and was accompanied by fever. Then, seizures became much less frequent. The patient's parents did not agree with the use of any AED because the parents were able to tolerate the seizures, which occurred at intervals of several months. The longest interval was 14 months. However, the seizures persisted, which were mostly accompanied by fever. The EEGs were normal at 4 months and 25 days of age and abnormal at 3 years and 5 months of age with slow background and occasionally atypical spikes in the central area on the left. Brain MRI had slightly widened subarachnoid space at 7 months of age and was normal at 22 months of age. MLPA test showed negative SCN1A CNV result ( Supplementary Fig. S3B) .
Patient 3 was a 17-month-old girl with epilepsy and mild DD. Her age of seizure onset was 5 months, and it was presented as clustered seizures with a frequency of five times in three days, each lasting for approximately 1 minute. From six to eight months of age, seizure occurred only once, but clustered seizures re-occurred after nine months, each lasting for approximately 1-3 min. Epilepsy was controlled for 3 months until the present time with LEV and OXC treatment. The patient's EEG was normal at the age of 9 and 10 months. The brain MRI showed delayed myelination at the age of five months.
The mutated amino acids of CSNK2B in patients 4 and 6 were the same. However, the amino acid changed from cystine to glycine (c.409 T > G, p.C137G) in patient 4 and from cystine to phenylalanine (c.410 G > T, p.C137F) in patient 6. The ages of seizure onset in patients 4 and 6 were two and six months, respectively. Both patients had clustered seizures, and their seizure type was GTCS. Within the first month of seizure onset, more than 10 episodes of seizures were observed, each lasting for 1-2 min. They did not have developmental delay. Their interictal EEGs were abnormal and similar (Table 3) . Their brain MRI results were normal. The seizures in patients 4 and 6 were controlled with monotherapy or polytherapy.
Patient 5 was a boy with the age of 1 year and 8 months, having an epilepsy but without ID/DD. The age of seizure onset was 6 months, and seizures occurred more than 10 times in the first month. The seizure type was GTCS. Seizure has been controlled for 1 year and 3 months until the present time.
Patient 8 was a 16-month-old girl with epilepsy and mild DD. The seizure type was GTCS, and half of the seizures were accompanied by fever. Epilepsy was under control for seven months with LEV treatment. MLPA test showed a negative SCN1A CNV result ( Supplementary Fig. S3C www.nature.com/scientificreports www.nature.com/scientificreports/ clinical features as patient 8, except for the absence of fever during seizures. His seizure had been controlled for 14 months with polytherapy.
In this study, only patient 9 had a splicing variant in CSNK2B. She is now 6 months old and has mild DD. The age of seizure onset was 3.5 months. The seizure type was GTCS, which was presented as clustered seizures, with a frequency of three times in 10 days, each lasting for 3-5 min. Seizure was controlled for more than two months.
Discussion
CSNK2B encodes the beta subunit of CK2, a ubiquitous protein kinase that regulates signal transduction, metabolic pathways, replication, transcription and translation. CK2 consists of three subunits, alpha, beta and alpha prime, which form a tetrameric holoenzyme. The alpha and alpha prime subunits are catalytic and the beta subunit has a regulatory functions.
CSNK2B splice site mutations has been reported in two patients with ID with or without myoclonic epilepsy 20 . The patient with myoclonic seizures (c.175 + 2 A > G) had refractory epilepsy, which occurred at the age of 18 months, and no remarkable improvement was found after LEV and VPA treatment. Then, a study reported a truncating mutation in CSNK2B (c.108dup) that causes myoclonic epilepsy and ID 21 . Antiepileptic treatment with VPA and LEV cured both epileptic myoclonus and complex partial seizures at the age of 15 months. The brain MRIs of these three patients in a previous report were all normal. Recently, another study reported two severe patients 22 , who both had seizures at the age of 2 months, which were refractory to polytherapy. One of the two patients developed a Lennox-Gastaut syndrome and GTCS from facial clonic seizures at the age of nine years. The other patient presented focal seizures on the 5th day after birth with a frequency of two or three times per day at the age of 7 years. Both patients had severe psychomotor impairment, were bedridden, and were not able to speak any meaningful words.
The relationship between the mutations in CSNK2B and related disease has not yet been cited in the OMIM database possibly due to the small number of cases. We presented nine cases with de novo variants in CSNK2B. These subjects, whether with a missense, frameshift, nonsense, or splicing variant, all had seizures. Six of them www.nature.com/scientificreports www.nature.com/scientificreports/ also had ID/DD. Bioinformatics analysis supported the deleterious effect in CSNK2B at the gene and variant levels, and all the variants are classified into pathogenic or likely pathogenic on the basis of the guideline proposed by ACMG. The age of seizure onset of all nine probands was less than 12 months, and the eight probands were below the age of six months. Eight out of nine (88.9%) cases had GTCS as the only seizure type. Cluster seizures occurred in 66.7% (6/9) patients. Most cases had normal EEG (5/9) and brain MRI (7/9). Seven patients (7/9, 77.8%) became seizure free with monotherapy or combination therapy. Only one patient did not undergo any treatment, because her parents were able to control her infrequent and non-severe seizures. Her seizures were recurrent from four months after birth until the age of three years and 5 months. Her EEG changed from normal to abnormal. One of the nine patients in this study and two patients reported in a previous study showed myoclonic epilepsy. Two of them had refractory epilepsy, while the other had an epilepsy controlled via VPA and LEV treatment. LEV is the most commonly used drug in seizure-free patients (5/7). Four patients became seizure free after monotherapy (two patients with LEV, and the two other patients with VPA and TPM). Three patients became seizure free with polytherapy (two patients with LEV and OXC, the another with TPM, OXC and LEV). Thus, CSNK2B-related epilepsy mostly had an early onset, and GTCS was the most common seizure type. Seizures are often clustered and could be recurrent for a long time if left untreated with AEDs, although seizures are easily controlled. Myoclonic seizures might predict AED resistance.
Three of the seven seizure-free patients had normal intelligence or developmental milestone. No improvement was observed in the intelligence and development of the four other patients with ID/DD after being seizure-free for an average of nine months (in the range 2-15 months). This finding suggests that ID/DD is a common comorbidity of CSNK2B-related epilepsy and will persist even if seizures have been controlled. CK2 is much more abundant in the brain than in any other tissue 32 . The number of dendrites, dendritic length and branch points are remarkably reduced in neurons after CSNK2B knockdown; moreover, CSNK2B in neurons remarkably alters the amplitude of miniature inhibitory postsynaptic currents and the frequency of miniature excitatory postsynaptic currents, thereby suggesting that CSNK2B is required for normal synaptic transmission 24 . Recently, Huillard et al. 23 found that conditional knockout of csnk2b in mice, lead to defects in the differentiation of embryonic neural stem cells. Moreover, Csnk2b positively regulates the development of oligodendrocyte precursor cells by interacting with transcription factor Olig2. CSNK2B plays an important role in brain development. However, its function in neurons remains poorly understood, and a detailed mode for its regulation has not been established. This finding might explain why ID/DD is the common co-morbidity in CSNK2B-related epilepsy. Spatio-temporal expression pattern analysis in developing prefrontal cortex shows that the mRNA expression levels of CSNK2B were higher at the early developmental stage (i.e., from eight post-conception weeks to four months of age) than at childhood and adulthood stages 24 . The early onset of CSNK2B-related epilepsy may be related to the high expression at the early stage of infancy.
Notably, PCDH19-related epilepsy has similar characteristics as CSNK2B-related epilepsy 33 , such as clustered seizures and early onset (<1 year) and is often associated with ID. PCDH19-related epilepsy is characterised by fever sensitivity. CSNK2B-related epilepsy had some seizures occurred during febrile disease, but, unlike PCDH19-related epilepsy, the seizures does not have significant fever sensitivity. PCDH19-related epilepsy was X-linked inherited in which patients are mainly females with heterozygous variants, or very few males with somatic mosaic mutations. CSNK2B-related epilepsy was autosomal dominant inherited, and both men and women were equally affected.
CSNK2B has several domains, such as Asp/Glu-rich (acidic), zinc-binding and interaction with α subunit domains. Six variants, including the reported variant c.367 + 2 A > G, are located in the zinc-binding domain, which might be important and hotspot domains related to this type of epilepsy. However, all the five patients with variants in the zinc-binding domain became seizure free. Hence, the seizures of the patients with variants in the domain of zinc-binding were easily controlled. The variant of patient 1 was next to the domain of interaction with α subunit, and the patient with a splicing variant in the acidic domain had refractory myoclonic epilepsy. Hence, the patients with variants related to interaction with α subunit and acidic domains had severe and refractory epilepsy. However, a severe phenotype could occur in patients with missense (patient 1 and reported c.494 A > G), frameshift (reported c.533_534insGT) or splice variation (reported c.175 + 2 A > G). The mild phenotype could occur in patients with missense, splice, frameshift, or nonsense variation. Therefore, we cannot establish a definite correlation between the phenotype and genotype in CSNK2B-related epilepsy at this time.
In conclusion, our research further demonstrated that pathogenic variants in CSNK2B were associated with epilepsy with or without ID/DD. CSNK2B-related epilepsy always starts early, and GTCS is the most common seizure type. In this type of epilepsy, seizures may recur over time if without treatment, and were often cluster, but these seizures were always easy to control, except that myoclonic seizures were refractory. LEV is the preferred AED. The zinc binding domain is the hotspot region for mutation.
